LifeStance Health Raises Price Target to $10 After 17% Q4 Revenue Growth
Canaccord raised its LifeStance Health Group price target to $10 from $9 following fiscal Q4 revenue of $382.2 million, up 17% year-over-year, and a clinician base expansion to 8,040. The company projects 2026 revenues of $1.615–$1.655 billion, center margin of $526–$550 million, and adjusted EBITDA of $185–$205 million.
1. Fiscal Q4 Performance
LifeStance reported fiscal Q4 revenue of $382.2 million, a 17% year-over-year increase, with visit volumes rising 18% to 2.4 million and the clinician base growing 9% to 8,040 professionals.
2. Analyst Price Target Increase
Canaccord maintained a Buy rating while boosting its price target on LifeStance to $10 from $9, citing sustained reimbursement rates, favorable utilization trends and robust Q4 results as catalysts.
3. FY 2026 Outlook
For fiscal 2026, the company forecasts revenue between $1.615 billion and $1.655 billion, center margins of $526 million to $550 million and adjusted EBITDA in the $185 million to $205 million range.